Press Release
SHANGHAI, CHINA — May 2026 — DROFEN MACHINERY EQUIPMENT CO., LTD, a specialized Turnkey CDMO equipment partner for injectable drug delivery device manufacturing, today announced the commercial launch of its next-generation High-Speed Insulin Pen Final Assembly Line, achieving a stable production output of 160 finished units per minute with 100% inline functional testing on every device.
This new system represents a significant advancement in injection pen manufacturing capability, addressing the urgent capacity demands driven by the global GLP-1 receptor agonist boom and the 2026 patent cliff that is opening biosimilar insulin markets across India, Southeast Asia, the Middle East, and Latin America.
BREAKTHROUGH SPEED WITHOUT COMPROMISING QUALITY
The DROFEN High-Speed Final Assembly Line integrates pre-filled drug cartridges with pre-assembled pen bodies into finished, patient-ready injection pen devices at 160 units per minute — a throughput level previously achievable only by European systems costing significantly more. What distinguishes the DROFEN system is that this speed is achieved while maintaining 100% inline functional testing, meaning every single device is individually verified for dose accuracy, button actuation force, dial torque, and visual conformity before leaving the production line.
"In the injection pen industry, speed without quality is meaningless," said Jordan Xu, Sales Director of DROFEN MACHINERY. "Our customers are pharmaceutical manufacturers who must meet FDA, EMA, and WHO prequalification standards. They cannot accept statistical sampling — they need 100% verification at full production speed. That is exactly what this system delivers."
KEY TECHNICAL CAPABILITIES
The new final assembly line features servo-controlled assembly stations with real-time force-displacement monitoring at every critical operation.
The system records complete mechanical fingerprints for each assembled device, supporting full traceability from individual component serial numbers through to finished device identification — fully compliant with FDA 21 CFR Part 11 and EU Annex 11 electronic batch record requirements.
The system accommodates multiple pen device platforms including disposable insulin pens, reusable insulin pens, GLP-1 receptor agonist pens, and autoinjector configurations. Changeover between pen variants is accomplished in under 45 minutes through quick-change tooling modules with automatic recipe loading.
Production specifications include compatibility with standard ISO 11608-compliant cartridges in both 1.5 mL and 3.0 mL configurations, dose setting ranges from 0.5 IU to 80 IU, and operation under ISO Class 7 cleanroom conditions.
The system targets an Overall Equipment Effectiveness (OEE) of 85% or higher under standard 24/7 production conditions.
TURNKEY CDMO APPROACH ELIMINATES INTEGRATION RISK
Unlike traditional equipment suppliers who deliver standalone machines, DROFEN MACHINERY provides its final assembly line as part of a complete Turnkey CDMO project solution. This integrated approach includes device platform coordination through the Wanhai Medical – DROFEN Joint Platform, in-house mold design and fabrication for pen body components, process validation documentation (DQ, FAT, IQ, OQ, PQ protocols), and regulatory submission support for global markets.
"The biggest risk in injection pen manufacturing is not the equipment itself — it is the integration gap between the device platform, the assembly machine, and the validation documentation," said Jordan Xu. "When these come from three different vendors, the pharmaceutical company is left to manage the interfaces alone. Our Turnkey approach eliminates that risk entirely. We take single-source accountability for the complete manufacturing capability."
DROFEN MACHINERY compresses typical project timelines from 12-18 months to just 6-9 months from order confirmation to Site Acceptance Test (SAT) completion, enabling pharmaceutical manufacturers to capture market windows faster than competitors relying on traditional European procurement channels.
ADDRESSING THE GLOBAL CAPACITY GAP
The launch of this system is strategically timed to address a critical capacity gap in the global injection pen market. With the pen injector market projected to reach $95 billion by 2034 and major insulin patents expiring in 2025-2026, biosimilar manufacturers worldwide are racing to establish injection pen production capabilities.
DROFEN MACHINERY's India branch provides dedicated local engineering support with 24-hour on-site response capability, serving the rapidly growing South Asian pharmaceutical manufacturing sector. The company also maintains service partnerships covering Southeast Asia, the Middle East, and Latin America.
ABOUT DROFEN MACHINERY
DROFEN MACHINERY EQUIPMENT CO., LTD is a specialized Turnkey CDMO equipment partner headquartered in Shanghai, China. The company focuses on two core pharmaceutical production lines: injection pen assembly lines and pre-filled syringe (PFS) filling lines.
DROFEN bridges the gap between mechanical assembly and pharmaceutical compliance, providing integrated solutions covering equipment delivery, device platform support, and regulatory-validation documentation.
The company serves pharmaceutical manufacturers, CDMOs, and biosimilar producers worldwide with a commitment to making injection pen and PFS projects successful — on time, on budget, and fully compliant.
For more information, visit:
CONTACT: Jordan Xu, Sales Director
DROFEN MACHINERY EQUIPMENT CO., LTD
Email: [email protected]
Website: www.drofen-pharma.com
Companies Mentioned
Business Categories Mentioned
